Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...

Findings from Spherix Global Insights’ research reveal nearly three-quarters anticipate frontline use, with significant ...

Relapsed and refractory multiple myeloma can be difficult to manage, especially as patients progress through multiple lines of therapy and treatment options may become more limited. 1 Since the ...

Today, there are more highly effective options for the treatment of newly diagnosed multiple myeloma than ever before, and more are on the way. Novel drug regimens, autologous stem cell transplant ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

Luciano Costa, MD, PhD, discusses the considerations for managing infection risk with bispecific antibodies in multiple ...

Multiple myeloma is a cancer of plasma cells in the bone marrow. While it is still considered incurable, treatments have improved significantly in recent years, helping patients live longer and feel ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...

Common manifestations and complications of multiple myeloma (MM) can include bone complications, hypercalcemia, renal insufficiency, infection, skeletal lesions and anemia. Other less common ...

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX ...

Johnson & Johnson (J&J) has announced US FDA approval for Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat adults with relapsed or refractory multiple ...